Results: nab-P + Gem demonstrated superior survival vs Gem alone, independent of the primary tumor location (Table) . Tumor location did not appear to be associated with any differences in treatment exposure. The median cumulative dose of nab-P was 1500 mg/m 2 vs 1375 mg/m 2 in pts who had primary tumors in the head vs tail or body. The most common grade ≥ 3 adverse events in pts with pancreatic head tumors for nab-P + Gem vs Gem (neutropenia [35% vs 26%], peripheral neuropathy [21% vs 1%], and fatigue [18% vs 9%]) were similar to those in the intent-to-treat (ITT) population. 
